In the first case of securities fraud related to COVID-19 to be brought before a US court, prosecutors charged the president of a California-based medical technology company with defrauding investors, manipulating stock prices and submitting fraudulent claims for allergy and coronavirus testing from which he allegedly made US$69 million.